tag:blogger.com,1999:blog-2741672436160438708.post4158809506886548207..comments2024-03-26T12:50:32.070-07:00Comments on Learning from and about cancer (chronic lymphocytic leukemia or CLL) by Dr. Brian Koffman: ASH 2012: Combinations of the PI3K∂ Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory CLLBrian Koffmanhttp://www.blogger.com/profile/13250684684103918493noreply@blogger.comBlogger4125tag:blogger.com,1999:blog-2741672436160438708.post-24598446950171539322013-01-01T14:56:51.045-08:002013-01-01T14:56:51.045-08:00The video will not play. Keeps telling me viedo is...The video will not play. Keeps telling me viedo is private ... Anonymoushttps://www.blogger.com/profile/05339239268565592492noreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-85292655413862066202012-12-21T13:41:37.901-08:002012-12-21T13:41:37.901-08:00Encouraging news for sure.Encouraging news for sure.Janet Morrisonnoreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-33709639013239161782012-12-21T10:34:41.029-08:002012-12-21T10:34:41.029-08:00As a PhD pharmacologist and a CLL patient, I can&#...As a PhD pharmacologist and a CLL patient, I can't wait to see the combination trial of GS-1101 and ibrutinib that most likely will occur at some point. Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-22547488010709774732012-12-19T13:14:55.434-08:002012-12-19T13:14:55.434-08:00WOW!!!! Keep the great news coming Brian!WOW!!!! Keep the great news coming Brian!Anonymousnoreply@blogger.com